Skip to main content
Fig. 3 | Cardiovascular Diabetology

Fig. 3

From: Role of Canagliflozin on function of CD34+ve endothelial progenitor cells (EPC) in patients with type 2 diabetes

Fig. 3

The effect of Canagliflozin on CD34+ve cell antioxidants gene expression. Fold change in gene expression of antioxidants SOD2 (a) in CD34+ve cells are increased in Canagliflozin group from visit 1 to 3. However, the same for the placebo group is decreased. Whereas the antioxidants, b Catalase (CAT) and c GPX3 gene expression increased in CD34+ve cells in Canagliflozin group from visit 2 to 3. However, the same for the placebo group is decreased. Overall, all the antioxidant genes showed increased expression going from visit 2 to visit 3, whereas the placebo there was a downward trend with catalase expression reaching statistical difference, overall

Back to article page